Clinical Trial Search

Primary: Overall Response by Radiologic Evaluation, Quality of Life Assessment, and Functional Impairment Score — 47; 7; 3 Participants

Primary: Frequency of Using Rose Application — 81; 79; 64; 134 # of hypnosis sessions listened to

Primary: Number of Participants With Adverse Drug Reactions (ADRs) — 3; 1 Participants

Primary: Area Under the Curve 0-24h — 281.60; 411.35 h*ng/mL

Primary: Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire — 4.47 score on a scale

Primary: Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory Abnormalities — 5; 4; 4; 12 Participants

Primary: Objective Response Rate (ORR) as Assessed Per RECIST v1.1 — 0; 11 Participants

Primary: Number of Participants With Dose Limiting Toxicities — 1; 0; 0 Participants

Primary: Pain Assessment Calculated as the Area Under the Curve of VAS Pain Intensity Scores Through 48 Hours After Surgery — 209.93; 253.53 VAS score*hour — p=<0.01

Primary: Preservation of Ejaculation — 34; 8 Participants

Primary: Main Study: Number of Participants With Histological Resolution of Nonalcoholic Steatohepatitis (NASH) Without Worsening of Fibrosis — 5; 12; 11; 1 Participants…

Primary: Mean Change in BCVA From Baseline in the Study Eye at the End of 12 Months — 11.17; 11.14 Letters

Primary: Myocardial Blood Flow — 1.60; 0.96; 2.40 mL/g/min

Primary: Image Quality — 6.6; 9.8; 11.2; 8.9 standard deviation of HU values

Primary: Change From Baseline in Physical Component Summary (PCS) of the Medical Outcomes Study Short-Form-36 (SF-36) at Week 12 — 29.47; 29.90; 30.06; 1.94 score on a scale…